Review of 2025

Genflow Biosciences PLC

08 January 2026

 

08 January 2026 

A Review of an Exciting 2025

2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs.

These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025.

Program Highlights

We've made a number of notable strides across our programs this year, including:

·      Dog Aging (GF-1004)

We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.

Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects.

·      MASH (GF-1002)

Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC.

We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development.

·      Glaucoma

In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.

We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us.

·      Additional Programs

We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs.

Looking Ahead to 2026

As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.

With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies.

Thank you for your continued support and confidence in Genflow.

Dr. Eric Leire 

Founder & Chief Executive Officer

Contacts

Genflow Biosciences	Harbor Access
Dr Eric Leire, CEO	Jonathan Paterson, Investor Relations
[phone]	[phone]
	[e-mail]

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com  and follow the Company on LinkedIn and X.

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

END